| Molecular regulations of circadian rhythm and implications for physiology and diseases F Fagiani, D Di Marino, A Romagnoli, C Travelli, D Voltan, ... Signal transduction and targeted therapy 7 (1), 41, 2022 | 231 | 2022 |
| Prostaglandin E2 and cancer: insight into tumor progression and immunity F Finetti, C Travelli, J Ercoli, G Colombo, E Buoso, L Trabalzini Biology 9 (12), 434, 2020 | 220 | 2020 |
| Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors U Galli, C Travelli, A Massarotti, G Fakhfouri, R Rahimian, GC Tron, ... Journal of medicinal chemistry 56 (16), 6279-6296, 2013 | 172 | 2013 |
| Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine AA Grolla, C Travelli, AA Genazzani, JK Sethi British journal of pharmacology 173 (14), 2182-2194, 2016 | 140 | 2016 |
| A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry G Colombano, C Travelli, U Galli, A Caldarelli, MG Chini, PL Canonico, ... Journal of medicinal chemistry 53 (2), 616-623, 2010 | 134 | 2010 |
| Characterization of NAD uptake in mammalian cells RA Billington, C Travelli, E Ercolano, U Galli, CB Roman, AA Grolla, ... Journal of Biological Chemistry 283 (10), 6367-6374, 2008 | 126 | 2008 |
| Recent advances in NAMPT inhibitors: a novel immunotherapic strategy U Galli, G Colombo, C Travelli, GC Tron, AA Genazzani, AA Grolla Frontiers in pharmacology 11, 656, 2020 | 122 | 2020 |
| NAD depletion by FK866 induces autophagy RA Billington, AA Genazzani, C Travelli, F Condorelli Autophagy 4 (3), 385-387, 2008 | 110 | 2008 |
| NAMPT: A pleiotropic modulator of monocytes and macrophages C Travelli, G Colombo, S Mola, AA Genazzani, C Porta Pharmacological research 135, 25-36, 2018 | 91 | 2018 |
| Nicotinamide phosphoribosyltransferase acts as a metabolic gate for mobilization of myeloid-derived suppressor cells C Travelli, FM Consonni, S Sangaletti, M Storto, S Morlacchi, AA Grolla, ... Cancer research 79 (8), 1938-1951, 2019 | 77 | 2019 |
| The NAMPT inhibitor FK866 reverts the damage in spinal cord injury E Esposito, D Impellizzeri, E Mazzon, G Fakhfouri, R Rahimian, C Travelli, ... Journal of neuroinflammation 9, 1-11, 2012 | 73 | 2012 |
| Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma AA Grolla, S Torretta, I Gnemmi, A Amoruso, G Orsomando, M Gatti, ... Pigment cell & melanoma research 28 (6), 718-729, 2015 | 69 | 2015 |
| Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions. E Maldi, C Travelli, A Caldarelli, N Agazzone, S Cintura, U Galli, ... Pigment cell & melanoma research 26 (1), 2013 | 67 | 2013 |
| Identification of novel triazole-based nicotinamide phosphoribosyltransferase (NAMPT) inhibitors endowed with antiproliferative and antiinflammatory activity C Travelli, S Aprile, R Rahimian, AA Grolla, F Rogati, M Bertolotti, ... Journal of medicinal chemistry 60 (5), 1768-1792, 2017 | 64 | 2017 |
| Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells C Travelli, V Drago, E Maldi, N Kaludercic, U Galli, R Boldorini, F Di Lisa, ... Journal of Pharmacology and Experimental Therapeutics 338 (3), 829-840, 2011 | 59 | 2011 |
| Discovery of highly potent benzimidazole derivatives as indoleamine 2, 3-dioxygenase-1 (IDO1) inhibitors: from structure-based virtual screening to in vivo pharmacodynamic activity M Serafini, E Torre, S Aprile, ED Grosso, A Gesù, A Griglio, G Colombo, ... Journal of medicinal chemistry 63 (6), 3047-3065, 2020 | 57 | 2020 |
| Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis G Colombo, N Clemente, A Zito, C Bracci, FS Colombo, S Sangaletti, ... Journal of Molecular Medicine 98, 595-612, 2020 | 52 | 2020 |
| Targeting transient receptor potential vanilloid 1 (TRPV1) channel softly: The discovery of passerini adducts as a topical treatment for inflammatory skin disorders M Serafini, A Griglio, S Aprile, F Seiti, C Travelli, F Pattarino, G Grosa, ... Journal of medicinal chemistry 61 (10), 4436-4455, 2018 | 46 | 2018 |
| OXER1 and RACK1-associated pathway: A promising drug target for breast cancer progression M Masi, E Garattini, M Bolis, D Di Marino, L Maraccani, E Morelli, ... Oncogenesis 9 (12), 105, 2020 | 40 | 2020 |
| Design, synthesis, and biological evaluation of combretabenzodiazepines: a novel class of anti-tubulin agents U Galli, C Travelli, S Aprile, E Arrigoni, S Torretta, G Grosa, A Massarotti, ... Journal of medicinal chemistry 58 (3), 1345-1357, 2015 | 40 | 2015 |
